Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SCO-240 by Scohia Pharma for Growth Hormone Deficiency: Likelihood of Approval
SCO-240 is under clinical development by Scohia Pharma and currently in Phase I for Growth Hormone Deficiency. According to GlobalData,...
SCO-267 by Scohia Pharma for Obesity: Likelihood of Approval
SCO-267 is under clinical development by Scohia Pharma and currently in Phase I for Obesity. According to GlobalData, Phase I...
SCO-240 by Scohia Pharma for Cholelithiasis: Likelihood of Approval
SCO-240 is under clinical development by Scohia Pharma and currently in Phase I for Cholelithiasis. According to GlobalData, Phase I...
SCO-267 by Scohia Pharma for Diabetes: Likelihood of Approval
SCO-267 is under clinical development by Scohia Pharma and currently in Phase I for Diabetes. According to GlobalData, Phase I...
SCO-267 by Scohia Pharma for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
SCO-267 is under clinical development by Scohia Pharma and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...
Imarikiren by Scohia Pharma for Diabetic Nephropathy: Likelihood of Approval
Imarikiren is under clinical development by Scohia Pharma and currently in Phase II for Diabetic Nephropathy. According to GlobalData, Phase...
Sucunamostat by Scohia Pharma for Phenylketonuria (PKU): Likelihood of Approval
Sucunamostat is under clinical development by Scohia Pharma and currently in Phase I for Phenylketonuria (PKU). According to GlobalData, Phase...
Sucunamostat by Scohia Pharma for Homocystinuria: Likelihood of Approval
Sucunamostat is under clinical development by Scohia Pharma and currently in Phase I for Homocystinuria. According to GlobalData, Phase I...
Sucunamostat by Scohia Pharma for Maple Syrup Urine Disease: Likelihood of Approval
Sucunamostat is under clinical development by Scohia Pharma and currently in Phase I for Maple Syrup Urine Disease. According to...
Sucunamostat by Scohia Pharma for Nephrotic Syndrome: Likelihood of Approval
Sucunamostat is under clinical development by Scohia Pharma and currently in Phase I for Nephrotic Syndrome. According to GlobalData, Phase...